Zolephos 5mg/100ml Infusion contains zoledronic acid, a potent bisphosphonate indicated for the treatment of various bone-related conditions including osteoporosis, Paget’s disease of bone, and hypercalcemia of malignancy. Zoledronic acid acts by inhibiting osteoclast-mediated bone resorption, thereby improving bone mineral density and reducing the risk of fractures. This intravenous infusion is administered as a 5mg dose diluted in 100ml of compatible fluid, typically given once yearly for osteoporosis or as per specific oncology protocols for bone metastases and hypercalcemia. Zolephos is contraindicated in patients with hypersensitivity to zoledronic acid or other bisphosphonates, severe renal impairment, or hypocalcemia. Prior to administration, calcium levels should be corrected, and renal function monitored due to potential nephrotoxicity. Common adverse effects include acute phase reactions such as fever, myalgia, and flu-like symptoms, which are generally transient. Adequate hydration before and after infusion is recommended to minimize renal risk. Zolephos should be used under strict medical supervision with appropriate monitoring to ensure efficacy and safety. This formulation provides a convenient and effective option for managing bone disease associated with malignancy and metabolic bone disorders.